Oppenheimer Asset Management Inc. Trims Stock Position in Humana Inc. (NYSE:HUM)

Oppenheimer Asset Management Inc. decreased its position in Humana Inc. (NYSE:HUM) by 1.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,647 shares of the insurance provider’s stock after selling 310 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Humana were worth $6,223,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Creative Financial Designs Inc. ADV raised its position in Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 61 shares in the last quarter. CarsonAllaria Wealth Management Ltd. increased its stake in shares of Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after buying an additional 39 shares during the period. Atwood & Palmer Inc. bought a new stake in shares of Humana in the third quarter valued at about $29,000. Ashton Thomas Securities LLC purchased a new stake in Humana in the third quarter worth about $31,000. Finally, Your Advocates Ltd. LLP grew its holdings in Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after acquiring an additional 45 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Trading Down 2.2 %

Shares of NYSE:HUM opened at $282.97 on Friday. The business has a 50-day moving average price of $284.64 and a 200-day moving average price of $332.14. The stock has a market cap of $34.07 billion, a price-to-earnings ratio of 25.06, a PEG ratio of 2.21 and a beta of 0.52. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $527.18. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The company had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Equities analysts predict that Humana Inc. will post 15.83 EPS for the current year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.25%. Humana’s payout ratio is currently 31.36%.

Analyst Upgrades and Downgrades

HUM has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Humana from $349.00 to $250.00 and set a “hold” rating for the company in a report on Thursday, October 3rd. Jefferies Financial Group downgraded shares of Humana from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $519.00 to $253.00 in a research note on Monday, October 7th. TD Cowen increased their target price on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Leerink Partners downgraded Humana from an “outperform” rating to a “market perform” rating and cut their price target for the company from $400.00 to $250.00 in a report on Wednesday, October 2nd. Finally, Piper Sandler cut Humana from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $392.00 to $274.00 in a research note on Thursday, October 3rd. Twenty investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.